[go: up one dir, main page]

Rao et al., 1990 - Google Patents

Technetium (V) and rhenium (V) complexes of 2, 3-bis (mercaptoacetamido) propanoate. Chelate ring stereochemistry and influence on chemical and biological …

Rao et al., 1990

Document ID
9167286207775083177
Author
Rao T
Adhikesavalu D
Camerman A
Fritzberg A
Publication year
Publication venue
Journal of the American Chemical society

External Links

Snippet

Monoxo complexes of technetium (V) and rhenium (V) with 2, 3-bis (mercaptoacetamido) propanoate (map) have been synthesized. The complexes with general formula [PI14X][MO (map)](where X= As, P; M= Tc, Re) were characterized by 1R, visible-UV spectra, and …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0497—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules

Similar Documents

Publication Publication Date Title
Rao et al. Technetium (V) and rhenium (V) complexes of 2, 3-bis (mercaptoacetamido) propanoate. Chelate ring stereochemistry and influence on chemical and biological properties
Jurisson et al. Synthesis, characterization, and x-ray structural determinations of technetium (V)-oxo-tetradentate amine oxime complexes
Rose et al. Synthesis and Characterization of Organohydrazino Complexes of Technetium, Rhenium, and Molybdenum with the {M (η1-H x NNR)(η2-H y NNR)} Core and Their Relationship to Radiolabeled Organohydrazine-Derivatized Chemotactic Peptides with Diagnostic Applications
JPWO2019065774A1 (en) Radioactive drug
Hashimoto et al. Rhenium complexes labeled with 186,188 Re for nuclear medicine
Volkert et al. Technetium-99m chelates as radiopharmaceuticals
Bisunadan et al. Synthesis and characterization of [186Re] rhenium (V) dimercaptosuccinic acid: a possible tumour radiotherapy agent
KR20050033067A (en) Radioactively labelled amino acid analogues, their preparation and use
JPS58126817A (en) Manufacture of radioactive nuclide mark protein, particularly, antibody or antibody piece
Duatti et al. Formation of the TcN multiple bond from the reaction of ammonium pertechnetate with S-methyl dithiocarbazate and its application to the preparation of technetium-99m radiopharmaceuticals
Lipowska et al. fac-99mTc/Re-tricarbonyl complexes with tridentate aminocarboxyphosphonate ligands: Suitability of the phosphonate group in chelate ligand design of new imaging agents
Price et al. Amino acid based gallium-68 chelators capable of radiolabeling at neutral pH
WO2021019983A1 (en) Method for synthesizing zirconium complex
Lipowska et al. Monoanionic 99mTc-tricarbonyl-aminopolycarboxylate complexes with uncharged pendant groups: radiosynthesis and evaluation as potential renal tubular tracers
He et al. Initial evaluation of new 99mTc (CO) 3 renal imaging agents having carboxyl-rich thioether ligands and chemical characterization of Re (CO) 3 analogues
Babich et al. 99mTc-labeled chemotactic peptides: influence of coligand on distribution of molecular species and infection imaging properties. Synthesis and structural characterization of model complexes with the {Re (η2-HNNC5H4N)(η1-NNC5H4N)} core
Marchi et al. Synthesis of technetium (V)-nitrido complexes with chelating amines: a novel class of monocationic, octahedral complexes containing the [Tc. tplbond. N] 2+ core. Crystal structures of [TcN (en) 2Cl]+(en= ethylenediamine) and [TcN (tad) Cl]+(tad= 1, 5, 8, 12-tetraazadodecane)
Sanders et al. Synthesis, characterization and biological studies of rhenium, technetium-99m and rhenium-188 pentapeptides
Tsoukalas et al. Characterization and preliminary evaluation of ester-modified technetium-99m SNS/S mixed ligand complexes as potential brain perfusion agents
Herscheid et al. N-Succinyldesferrioxamine B: a potential radiopharmaceutical for assessing renal function
Tsotakos et al. Benzimidazole derivatives as NSO ligands for the fac-[M (CO) 3]+(M= Re, 99mTc)
Papadopoulos et al. Synthesis and characterization of five-coordinate rhenium (V) and technetium (V) mixed ligand bifunctional complexes carrying the SNS/S or the SNN/S donor atom set. Crystal structure of ReO {[(C2H5) 2NCH2CH2N (CH2CH2S) 2](p-H2N–PhS)} and ReO {[(CH2) 4NCH2CH2NCH2CH2S](p-H2N–PhS)}
Aulsebrook et al. Highlights of radioisotope, radiochemistry, and radiotracer development in Australia
Marmion et al. Synthesis and characterization of novel N3O3-Schiff base complexes of 99gTc, and in vivo imaging studies with analogous 99mTc complexes
Leenhardt et al. TrisOxine abiotic siderophores for technetium complexation: radiolabeling and biodistribution studies